

Effect of Smart Wearable Glucose Monitors on Hypoglycemia Incidence in Diabetic Adults with Malaria in Sub-Saharan Africa

Ivan Mutebi

Department of Pharmacognosy Kampala International University Uganda

Email: ivan.mutebi@studwc.kiu.ac.ug

ABSTRACT

Diabetes mellitus and malaria represent a critical dual burden in sub-Saharan Africa (SSA), where the intersection of non-communicable and infectious diseases intensifies clinical complexity. In diabetic adults, malaria-induced metabolic stress exacerbated by fever, reduced appetite, and antimalarial treatments often precipitates episodes of hypoglycemia, a life-threatening complication that remains under-monitored due to limited access to conventional glucose testing methods. Smart wearable glucose monitors (SWGMs), particularly continuous glucose monitoring systems, provide real-time, continuous glycemic data and hold promise for reducing hypoglycemia by enabling proactive insulin adjustments and dietary interventions during acute febrile illness. This review evaluated the effectiveness of SWGMs in mitigating hypoglycemic risk among diabetic adults co-infected with malaria in SSA. A narrative review methodology was employed, synthesizing evidence from peer-reviewed literature, technological reports, and implementation case studies. Findings revealed that SWGMs improve glycemic control and reduce hypoglycemia incidence in various settings; however, data specific to malaria-diabetes comorbidity in SSA remain limited. Challenges such as device cost, health infrastructure deficits, digital illiteracy, and sociocultural resistance hinder widespread adoption. The review underscored the need for context-specific clinical trials, government-subsidized procurement models, mobile health integration, and culturally sensitive educational strategies. With strategic investment and policy support, SWGMs could become a transformative tool in improving outcomes for this medically vulnerable population in SSA.

Keywords: Smart Wearable Glucose Monitors, Hypoglycemia, Diabetes Mellitus, Malaria Co-infection, Sub-Saharan Africa.

INTRODUCTION

Diabetes mellitus, particularly type 2 diabetes (T2DM), has emerged as a major public health concern in sub-Saharan Africa (SSA), a region historically burdened by communicable diseases such as malaria [1, 2]. The intersection of these two conditions creates a complex clinical landscape, especially given their opposing metabolic implications. Malaria, caused predominantly by *Plasmodium falciparum* in SSA, induces systemic inflammation, fever, and anorexia, which can significantly alter glucose homeostasis [3, 4]. In diabetic individuals, this co-infection often precipitates episodes of hypoglycemia, especially when treatment regimens are not adequately adjusted to reflect the fluctuating metabolic demands imposed by acute febrile illness.

Smart wearable glucose monitors (SWGMs), such as continuous glucose monitoring (CGM) systems, represent a novel technological intervention that may help mitigate hypoglycemic risk by providing real-time glucose data, trend alerts, and actionable insights to patients and healthcare providers [5]. These devices have shown promising outcomes in high-resource settings but remain underutilized and understudied in SSA, where healthcare infrastructure, economic constraints, and disease epidemiology differ significantly. The integration of SWGMs into malaria-endemic regions could revolutionize diabetes management by enabling dynamic insulin adjustments during periods of febrile illness, preventing complications related to hypoglycemia, and improving overall glycemic control [6]. However, the adoption of such technology requires consideration of numerous contextual factors including cost, accessibility, cultural acceptance, and the capacity of health systems to interpret and act on the data.

This narrative review critically explores the potential impact of smart wearable glucose monitors on hypoglycemia incidence in diabetic adults co-infected with malaria in SSA. It synthesizes evidence from existing literature, highlights technological advances, and discusses contextual challenges and opportunities in implementing this novel intervention. The objective is to provide a nuanced understanding of how SWGMs can transform clinical outcomes in this unique patient population, while offering a foundation for future research and policy direction.

DIABETES AND MALARIA: A DUAL BURDEN IN SSA

Sub-Saharan Africa faces the dual burden of infectious and non-communicable diseases (NCDs), with malaria and diabetes forming a clinically challenging interface [7]. Diabetes, particularly T2DM, is rising rapidly in the region, driven by urbanization, sedentary lifestyles, and dietary shifts [8]. Concurrently, malaria remains endemic, with seasonal surges causing high morbidity and mortality [9]. The coexistence of these diseases creates unique clinical vulnerabilities, especially in adults who must manage lifelong glycemic control while facing recurrent episodes of malaria.

Malaria impacts glucose metabolism through multiple mechanisms. Acute infection increases metabolic demand and disrupts hepatic gluconeogenesis and glycogenolysis [10]. Moreover, antimalarial treatments especially quinine are known to induce hypoglycemia. In diabetic individuals already taking insulin or sulfonylureas, the risk is compounded. Fever, poor appetite, and vomiting during malaria episodes can lead to reduced oral intake, further destabilizing glucose levels and precipitating hypoglycemic events.

Hypoglycemia, defined as blood glucose <70 mg/dL, is particularly dangerous in individuals with diabetes, causing neuroglycopenic symptoms such as confusion, seizures, and even death if untreated [11, 12]. Recurrent hypoglycemia also impairs counter-regulatory hormonal responses, reducing the body's ability to self-correct glucose fluctuations. In low-resource settings, where glucose monitoring may be infrequent and clinical oversight limited, these episodes often go unnoticed or are misdiagnosed as malaria-related complications.

This clinical interplay demands precision in glucose monitoring, particularly during febrile illnesses. Traditional self-monitoring methods using fingerstick tests are episodic, invasive, and often underutilized due to cost and access issues. These limitations underscore the need for continuous, user-friendly, and context-appropriate monitoring systems. Smart wearable glucose monitors, which offer real-time data and hypoglycemia alerts, are increasingly relevant in such dual disease scenarios.

Understanding this dual burden is essential for identifying gaps in current care strategies and for appreciating how technology, particularly SWGMs, might address unmet clinical needs in diabetic adults with malaria in SSA.

SMART WEARABLE GLUCOSE MONITORS: TECHNOLOGY AND FUNCTION (350 words)

Smart wearable glucose monitors, commonly referred to as continuous glucose monitoring (CGM) systems, represent a significant advancement in diabetes care [13]. These devices consist of three main components: a subcutaneous sensor that measures interstitial glucose levels, a transmitter that sends data wirelessly, and a receiver or smartphone application that displays real-time glucose trends. Some advanced CGMs are integrated with insulin pumps to form closed-loop systems, although most operate independently as adjunct monitoring tools.

The core benefit of SWGMs lies in their ability to provide real-time and continuous data, typically updated every 5–15 minutes [14]. This granularity enables users to observe glucose trends, predict impending hypoglycemia, and respond proactively. Alerts and alarms can be customized to warn users of rapid glucose changes or specific thresholds, enhancing safety during sleep or illness two high-risk periods for hypoglycemia.

CGM technology can be categorized as either real-time CGM (rtCGM) or intermittently scanned CGM (isCGM) [15]. The former offers continuous feedback with predictive alerts, while the latter requires manual scanning to view data. Both types significantly reduce hypoglycemia rates compared to traditional fingerstick monitoring, as demonstrated in multiple clinical trials involving various diabetic populations.

The relevance of SWGMs in SSA, particularly during malaria co-infection, stems from their capacity to detect hypoglycemia early and reduce the risk of severe complications. During malaria episodes, glucose levels can drop rapidly due to fever, medication side effects, and decreased oral intake. Fingerstick testing, if done only once or twice daily, may miss these fluctuations. In contrast, SWGMs provide comprehensive glycemic profiles, enabling real-time insulin adjustment and dietary compensation.

Some models are factory-calibrated and can be worn for 10–14 days, reducing the burden of daily maintenance. However, their performance in febrile conditions or among individuals with altered skin perfusion such as during malaria needs further evaluation. Moreover, affordability, user training, and integration into existing health systems remain pivotal to successful deployment in SSA.

In summary, SWGMs represent a technologically robust, patient-centered tool that may be particularly effective in managing glycemic variability during acute infections like malaria.

EVIDENCE ON HYPOGLYCEMIA REDUCTION IN DIABETES USING SWGMs

The global literature supports the effectiveness of SWGMs in reducing hypoglycemic episodes among individuals with diabetes. Multiple randomized controlled trials and longitudinal cohort studies have demonstrated that CGM use leads to increased time in target glucose range, reduced nocturnal hypoglycemia, and improved patient confidence in managing diabetes.

For instance, landmark trials such as the DIAMOND and HypoDE studies showed significant reductions in both symptomatic and severe hypoglycemic episodes among insulin-treated adults using CGMs [16]. These benefits were particularly evident in patients with impaired hypoglycemia awareness, a common condition in long-standing diabetes.

While these findings are compelling, most originate from high-income settings. In the context of SSA, where febrile illnesses like malaria are prevalent, the pattern of glucose variability differs. Unfortunately, limited region-specific data exist on SWGM effectiveness during concurrent infections. However, extrapolating from known mechanisms, it is reasonable to infer that real-time glucose feedback can help mitigate the hypoglycemic effects of reduced intake, antimalarial therapy, and increased metabolic demand during malaria.

Emerging pilot studies from urban centers in SSA such as Kenya and Nigeria have begun exploring CGM feasibility, demonstrating good user acceptability, high data accuracy, and reduced hospital admissions due to hypoglycemia [17, 18]. Although these early studies are limited in scale and scope, they lay the groundwork for more targeted research on SWGMs in malaria-endemic populations.

Moreover, SWGMs may indirectly reduce hypoglycemia by empowering patients to self-manage more effectively and by enabling clinicians to personalize therapy during illness. Combined with digital health platforms, these monitors can transmit data to remote health teams, facilitating timely interventions in rural settings where access to care is limited.

In essence, while direct evidence of SWGM use in malaria-diabetes comorbidity is emerging, existing data strongly support their role in reducing hypoglycemia and improving safety in high-risk diabetic populations

IMPLEMENTATION CHALLENGES IN SUB-SAHARAN AFRICA

Despite the clinical promise of SWGMs, their implementation in SSA faces significant hurdles that must be acknowledged and addressed. First and foremost is the issue of cost [19]. Most smart glucose monitors are priced beyond the reach of average households in SSA, and national health insurance schemes rarely cover such devices. The high upfront costs for sensors, transmitters, and compatible smartphones limit widespread adoption.

Technological literacy and patient education also pose barriers SWGM in SSA. Many adults in rural areas may lack familiarity with mobile-based technologies or wearable sensors. Without proper training and follow-up, even the most sophisticated tools may go underutilized or misinterpreted. Healthcare workers, too, must be equipped to interpret CGM data and incorporate it into clinical decisions necessitating updates in curricula and continuous professional development.

Infrastructure challenges, such as unreliable internet access and electricity shortages, further complicate deployment. Even when devices are provided through donor-funded programs, their functionality can be compromised without consistent power or data connectivity. Battery-powered or offline-capable models may offer a partial solution, but such options are still evolving [20].

Cultural perceptions and stigma related to wearing visible medical devices may reduce adherence in some communities [21]. Myths around technology, diabetes, or foreign interventions can hinder acceptance unless addressed through robust community engagement.

Regulatory and supply chain limitations add another layer of complexity. Import restrictions, lack of regulatory approval for certain models, and inconsistent availability of sensors and transmitters make sustainability a key concern [22]. Governments and NGOs must work collaboratively to streamline procurement, negotiate prices, and ensure long-term availability.

Despite these challenges, the increasing penetration of mobile technology, growing health-tech ecosystems in African cities, and supportive global health partnerships provide a pathway forward. Strategic planning and community-centered implementation are critical to harnessing the full potential of SWGMs in SSA's diabetic population, particularly during malaria episodes.

FUTURE DIRECTIONS AND POLICY RECOMMENDATIONS

To optimize the use of smart wearable glucose monitors for hypoglycemia prevention in diabetic adults with malaria, a multipronged strategy is essential. Future research should prioritize context-specific clinical trials to evaluate SWGM efficacy during febrile episodes, particularly in malaria-endemic zones. These trials should stratify participants by disease severity, insulin regimen, and access to care to inform nuanced guidelines.

Public-private partnerships may help reduce device costs through bulk procurement, local manufacturing, or subsidy schemes [23]. Governments, NGOs, and private companies must align incentives to create scalable and sustainable

access models. Integrating SWGMs into universal health coverage (UHC) packages or essential medical devices lists could accelerate mainstream adoption.

Training and task-shifting should be embedded in roll-out plans. Primary healthcare workers, community health volunteers, and patients themselves must be trained to interpret CGM data, recognize alarm patterns, and adjust therapy or seek care appropriately. This is especially vital in rural or resource-constrained settings where physician oversight is intermittent.

Mobile health (mHealth) integration offers an exciting frontier. CGM data can be linked with mHealth platforms to enable remote monitoring, automated alerts, and decision-support tools for clinicians [24]. These features can create a virtual safety net for high-risk patients during malaria episodes.

Finally, community engagement is paramount. Educational campaigns that demystify diabetes, glucose monitoring, and wearable technology can reduce stigma and enhance uptake. Local leaders, traditional healers, and faith-based organizations should be included in advocacy to build trust and cultural relevance.

In sum, the integration of smart glucose monitors into diabetic care in SSA, especially during malaria episodes, represents a forward-looking solution to an urgent clinical challenge. With adequate support, this intervention could dramatically reduce hypoglycemia-related morbidity and mortality in one of the world's most vulnerable populations.

CONCLUSION

The co-occurrence of malaria and diabetes in sub-Saharan Africa presents a significant clinical challenge, particularly due to the increased risk of hypoglycemia during febrile illness. Traditional glucose monitoring methods are insufficient in capturing the dynamic glycemic fluctuations that accompany such infections. Smart wearable glucose monitors offer a novel and technologically advanced solution, capable of providing continuous, real-time insights into glucose patterns, thereby enabling timely interventions and reducing the incidence of hypoglycemia. While substantial evidence exists supporting the efficacy of SWGMs in diabetes management globally, their specific application in malaria-endemic settings remains underexplored. Nevertheless, the theoretical and emerging empirical support suggests significant promise. Implementation, however, is fraught with challenges including high costs, infrastructure limitations, and sociocultural barriers that must be systematically addressed. To fully realize the potential of SWGMs in reducing hypoglycemia among diabetic adults with malaria, there is a need for contextualized clinical trials, strategic investments, and health system strengthening. With an integrated approach that combines technological innovation, policy alignment, and community engagement, SWGMs could represent a pivotal advancement in chronic disease management across SSA. Their successful deployment could redefine standards of care for a growing population burdened by the dual threats of diabetes and malaria.

REFERENCES

1. Motala, A.A., Mbanya, J.C., Ramaiya, K., Pirie, F.J., Ekoru, K.: Type 2 diabetes mellitus in sub-Saharan Africa: challenges and opportunities. *Nat Rev Endocrinol.* 18, 219–229 (2022). <https://doi.org/10.1038/s41574-021-00613-y>
2. Ugwu, O.P.C., Kungu, E., Inyangat, R., Obeagu, E. I., Okon, M. B., Subbarayan, S. and Sankarapandian, V.: Exploring Indigenous Medicinal Plants for Managing Diabetes Mellitus in Uganda: Ethnobotanical Insights, Pharmacotherapeutic Strategies, and National Development Alignment. *INOSR ES.* 12, 214–224 (2023). <https://doi.org/10.59298/INOSRES/2023/2.17.1000>
3. Gupta, A.: *Nutritional Anemia in Preschool Children.* Springer, Singapore (2017)
4. Tufail, T., Agu, P.C., Akinloye, D.I., Obaroh, I.O.: Malaria pervasiveness in Sub-Saharan Africa: Overcoming the scuffle. *Medicine.* 103, e40241 (2024). <https://doi.org/10.1097/MD.0000000000040241>
5. Mohamed Yousuff, A.R., Zainulabedin Hasan, M., Anand, R., Rajasekhara Babu, M.: Leveraging deep learning models for continuous glucose monitoring and prediction in diabetes management: towards enhanced blood sugar control. *Int J Syst Assur Eng Manag.* 15, 2077–2084 (2024). <https://doi.org/10.1007/s13198-023-02200-y>
6. Agyare, G.: Effect of Diabetes and Malaria Comorbidity On Naturally Acquired Antibody Responses Against Malaria Vaccine Candidate Antigens, <http://ir.ucc.edu.gh/jspui/handle/123456789/11536>, (2024)
7. Goswami, N.: A Dual Burden Dilemma: Navigating the Global Impact of Communicable and Non-Communicable Diseases and the Way Forward. *International Journal of Medical Research.* 12, 65–77 (2024). <https://doi.org/10.55489/ijmr.123202412>
8. Alum, E.U.: Optimizing patient education for sustainable self-management in type 2 diabetes. *Discov Public Health.* 22, 44 (2025). <https://doi.org/10.1186/s12982-025-00445-5>

9. Aineboona, C., Egwu, C.O., Onohuean, H., Ugwu, O.P.-C., Uti, D.E., Echegu, D.A.: Mitigation of Malaria in Sub-Saharan Africa through Vaccination: A Budding Road Map for Global Malaria Eradication. *Ethiopian Journal of Health Sciences*. 35, (2025)
10. Von Ah Morano, A.E., Dorneles, G.P., Peres, A., Lira, F.S.: The role of glucose homeostasis on immune function in response to exercise: The impact of low or higher energetic conditions. *Journal of Cellular Physiology*. 235, 3169–3188 (2020). <https://doi.org/10.1002/jcp.29228>
11. Ikpozu, E.N., Offor, C.E., Igwenyi, I.O., Obaroh, I.O., Ibiam, U.A., Ukaidi, C.U.A.: RNA-based diagnostic innovations: A new frontier in diabetes diagnosis and management. *Diabetes & Vascular Disease Research*. 22, 14791641251334726 (2025). <https://doi.org/10.1177/14791641251334726>
12. Umoru, G.U., Uti, D.E., Aja, P.M., Ugwu, O.P., Orji, O.U., Nwali, B.U., Ezeani, N.N., Edwin, N., Orinya, F.O.: Hepato-Protective Effect of Ethanol Leaf Extract of *Datura stramonium* in Alloxan-Induced Diabetic Albino Rats. *Journal of Chemical Society of Nigeria*. 47, (2022). <https://doi.org/10.46602/jcsn.v47i5.819>
13. Zafar, H., Channa, A., Jeoti, V., Stojanović, G.M.: Comprehensive Review on Wearable Sweat-Glucose Sensors for Continuous Glucose Monitoring. *Sensors*. 22, 638 (2022). <https://doi.org/10.3390/s22020638>
14. Sharma, S., Sharma, K., Grover, S.: Real-Time Data Analysis with Smart Sensors. In: Gulati, S. (ed.) *Application of Artificial Intelligence in Wastewater Treatment*. pp. 127–153. Springer Nature Switzerland, Cham (2024)
15. Zhou, Y., Sardana, D., Kuroko, S., Haszard, J.J., de Block, M.I., Weng, J., Jefferies, C., Wheeler, B.J.: Comparing the glycaemic outcomes between real-time continuous glucose monitoring (rt-CGM) and intermittently scanned continuous glucose monitoring (isCGM) among adults and children with type 1 diabetes: A systematic review and meta-analysis of randomized controlled trials. *Diabetic Medicine*. 41, e15280 (2024). <https://doi.org/10.1111/dme.15280>
16. Ruedy, K.J., Parkin, C.G., Riddlesworth, T.D., Graham, C.: Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial. *J Diabetes Sci Technol*. 11, 1138–1146 (2017). <https://doi.org/10.1177/1932296817704445>
17. Ungaya, G.M.L.: Healthcare Provider Patient Communication on Diabetes Mellitus Management Practices in Selected Hospitals in Kenya, <http://localhost/xmlui/handle/123456789/6154>, (2023)
18. Billa, B., Kennedy, J.: Challenges and opportunities in managing Type 2 Diabetes Mellitus in Sub-Saharan Africa: the cases of Nigeria and South Africa, <https://reposit.haw-hamburg.de/handle/20.500.12738/13741>, (2023)
19. Manyazewal, T., Ali, M.K., Kebede, T., Solomon, S., Hailemariam, D., Patel, S.A., Escoffery, C., Woldeamanuel, Y., Marinucci, F., Joseph, M., Getinet, T., Amogne, W., Fekadu, A., Marconi, V.C.: Digital continuous glucose monitoring systems for patients with HIV-diabetes comorbidity in Ethiopia: a situational analysis. *Sci Rep*. 14, 28862 (2024). <https://doi.org/10.1038/s41598-024-79967-y>
20. Ezenwaji, C.O., Alum, E.U., Ugwu, O.P.-C.: The role of digital health in pandemic preparedness and response: securing global health? *Global Health Action*. 17, 2419694 (2024). <https://doi.org/10.1080/16549716.2024.2419694>
21. Spinelli, G., Micocci, Massimo, Martin, Wendy, and Wang, Y.-H.: From medical devices to everyday products: exploring cross-cultural perceptions of assistive technology. *Design for Health*. 3, 324–340 (2019). <https://doi.org/10.1080/24735132.2019.1680065>
22. Ugwu, O.P.-C., Alum, E.U., Ugwu, J.N., Eze, V.H.U., Ugwu, C.N., Ogenyi, F.C., Okon, M.B.: Harnessing technology for infectious disease response in conflict zones: Challenges, innovations, and policy implications. *Medicine (Baltimore)*. 103, e38834 (2024). <https://doi.org/10.1097/MD.00000000000038834>
23. Trebilcock, M., and Rosenstock, M.: Infrastructure Public–Private Partnerships in the Developing World: Lessons from Recent Experience. *The Journal of Development Studies*. 51, 335–354 (2015). <https://doi.org/10.1080/00220388.2014.959935>
24. Vadia, N., Patel, P., Sutariya, V.: Advances and Opportunities in Digital Diabetic Healthcare Systems. In: *Decision Support System for Diabetes Healthcare: Advancements and Applications*. River Publishers (2025)

Ivan Mutebi. Effect of Smart Wearable Glucose Monitors on Hypoglycemia Incidence in Diabetic Adults with Malaria in Sub-Saharan Africa EURASIAN EXPERIMENT JOURNAL OF BIOLOGICAL SCIENCES, 6(2):10-15.